Immatics NV (IMTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.62 (-2.27%), Market cap $1.45B, 52-week low–high $4.93 ~ $11.87.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's
Financial statements, price targets, institutional (13F) holdings and related news for Immatics NV are updated in real time on BlackAll Trade.
Immatics NV trades at $8.62 (-2.27%). Real-time quotes and charts are available on BlackAll Trade.
Immatics NV has a market cap of about $1.45B.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The